Management of Acute Tinnitus With Migraine Medications

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Jan 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain migraine medications can help people who suffer from acute tinnitus, which is a ringing or buzzing sound in the ears that can be very distressing. Tinnitus can affect a person's quality of life, leading to anxiety and stress. The researchers want to find out if these medications can reduce the loudness and frequency of tinnitus and improve daily functioning for those affected. There are currently no FDA-approved medications specifically for tinnitus, but this study aims to explore possible options.

To participate in this trial, you need to be between the ages of 25 and 85 and have mild to moderate tinnitus. It's important that you're willing to follow the treatment plan and attend study visits. Unfortunately, if you are pregnant or have had a bad reaction to the medications being tested, you won't be able to join. Those who participate will receive the medication and will have their tinnitus symptoms measured before and after treatment, along with some brain imaging to see how the treatment may be affecting them. This could be a valuable opportunity for those looking for relief from their tinnitus symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with mild to moderate tinnitus.
• • Male or female between the ages of 25 to 85 years.
• • Subjects must be compliant with the medication and attend study visits.
• • Must be able to read and write in the English language to provide consent.
• Exclusion Criteria:
• • Pregnancy will result in automatic exclusion from the study. Rule out of pregnancy will be done by urine pregnancy test to confirm the situation for all women who are of childbearing potential.
• • Subjects with a history of an adverse reaction to medication being prescribed.
• • Subjects suffering from a medical condition or have a history that may be concerning to the investigator's clinical opinion.
• • All contraindications for the medications that prevent subjects from randomization will be considered as exclusion criteria.